Tech Company Financing Transactions

ViaCyte Funding Round

ViaCyte closed a $5.4 million Series C financing round on 8/8/2014. Backers included private investors.

Transaction Overview

Company Name
Announced On
8/8/2014
Transaction Type
Venture Equity
Amount
$5,400,000
Round
Series C
Investors
Proceeds Purpose
The Company will use the funds to pursue clinical development of its VC-01� product candidate. ViaCyte also recently announced the submission of an Investigational New Drug application and a Medical Device Master File to the U.S. Food and Drug Administration seeking permission to begin clinical evaluation of the product candidate.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3550 General Atomics Ct.
San Diego, CA 92121
USA
Email Address
Overview
ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
Profile
ViaCyte LinkedIn Company Profile
Social Media
ViaCyte Company Twitter Account
Company News
ViaCyte News
Facebook
ViaCyte on Facebook
YouTube
ViaCyte on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Michael Yang
  Michael Yang LinkedIn Profile  Michael Yang Twitter Account  Michael Yang News  Michael Yang on Facebook
Chief Financial Officer
Brittany Bradrick
  Brittany Bradrick LinkedIn Profile  Brittany Bradrick Twitter Account  Brittany Bradrick News  Brittany Bradrick on Facebook
Chief Medical Officer
Howard Foyt
  Howard Foyt LinkedIn Profile  Howard Foyt Twitter Account  Howard Foyt News  Howard Foyt on Facebook
Chief Scientific Officer
Kevin D'Amour
  Kevin D'Amour LinkedIn Profile  Kevin D'Amour Twitter Account  Kevin D'Amour News  Kevin D'Amour on Facebook
Chief Technical Officer
Steve White
  Steve White LinkedIn Profile  Steve White Twitter Account  Steve White News  Steve White on Facebook
Vice President
Manasi Jaiman
  Manasi Jaiman LinkedIn Profile  Manasi Jaiman Twitter Account  Manasi Jaiman News  Manasi Jaiman on Facebook
VP - Finance
Anne Sandan
  Anne Sandan LinkedIn Profile  Anne Sandan Twitter Account  Anne Sandan News  Anne Sandan on Facebook
VP - General Counsel
Liz Bui
  Liz Bui LinkedIn Profile  Liz Bui Twitter Account  Liz Bui News  Liz Bui on Facebook
VP - Regulatory Affairs
Steve Kradjian
  Steve Kradjian LinkedIn Profile  Steve Kradjian Twitter Account  Steve Kradjian News  Steve Kradjian on Facebook


 

 

Browse more venture capital transactions:

Prev: 8/7/2014: Lifetime Oil venture capital transaction
Next: 8/8/2014: Aegis Mobility venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary